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Yasuko Fuse-Nagase1* and Toru Nishikawa2Abstract
A 30-year-old Japanese man with no previous psychiatric history presented to our facility with delusions, which had
been ongoing for 2 months. Upon further interview, he confided that he had a past history of recurrent 5-methoxy-N,
N-diisopropyltryptamine (5-MeO-DIPT or “Foxy”) abuse, as well as a recent history of recurrent ingestion of a legal
aromatic liquid used as a recreational drug. After this episode, his condition improved and he did not follow up at
subsequent appointments. However, 6 months later, he suffered a relapse of prolonged delusions after again ingesting
a recreational aromatic liquid. An evaluation of the chronological sequence of the patient’s condition revealed that
ingestion of these aromatic liquids, which can be purchased easily on the Internet, likely triggered the patient’s
delusional episodes. We speculate that the patient’s recurrent abuse of 5-MeO-DIPT caused sensitization (or reverse
tolerance), thus prolonging his delusions. Sensitization is the amplification of a response following repeated
administrations of a stimulus. 5-MeO-DIPT is a popular drug of abuse, and it is highly probable that a large number of
past 5-MeO-DIPT users are currently sensitized. This is an important latent factor underlying subsequent episode of
drug-induced psychosis. Psychiatrists should consider the possibility of 5-MeO-DIPT sensitization when evaluating
patients with acute psychoses.
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Abuse of commercially available incense, herbs, bath
salts, and aromatic liquids is a common social problem
in many countries [1,2]. Here, we report a case of a pa-
tient with a prolonged delusional episode after ingesting
a legal aromatic liquid. To the best of our knowledge,
there are no prior reports of prolonged delusions
triggered by abusing these commercially available
substances. In addition, the patient had a past history of
5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT or
“Foxy”) abuse, a hallucinogenic drug widely abused and
now illegal in many countries. We speculate that his past
history of 5-MeO-DIPT abuse was related to the pro-
longation of his delusions.* Correspondence: yfusen@mx.ibaraki.ac.jp
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Case description
A 30-year-old Japanese man with a normal developmental
history, and no personal or family history of prior psychia-
tric disease, presented with delusions in May 2011. The
patient was a university graduate and employed at a com-
pany. His past history included tuberculosis at age 27 years
old. His delusions consisted of persistent paranoid beliefs
that somebody was conducting audio surveillance of his
house and that his wife was having an affair, and he be-
came obsessed with trying to find hidden listening devices
and tracking his wife’s whereabouts. Worried about the
possibility of schizophrenia, his family brought him for
evaluation. Schizophrenia was ruled out since he did not
meet diagnostic criteria [3]: his psychiatric symptoms
lasted less than 6 months at first visit, he had no hallucina-
tions, his speech was not disorganized, his behavior was
neither disorganized nor catatonic, and he showed no
clear negative symptoms. The patient was empirically
started on oral olanzapine 5 mg/day.BioMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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following three months. During follow up psychiatric
evaluation, he expressed that it was maladaptive to obsess
about his paranoid delusions. However, he complained
that he felt restless, apathetic, and drowsy, in addition to
gaining weight. Olanzapine was first reduced to 2.5 mg/day,
and then replaced with aripiprazole 12 mg/day.
Three months later (November 2011), he confided that
he had a history of 5-methoxy-N,N-diisopropyltryptamine
(5-MeO-DIPT) ingestion, which he began abusing at 18 or
19 years old. He used this substance approximately 10
times and quit when he was 21 years old. However, about
1 year prior to his initial presentation, he had started
ingesting a commercially available aromatic liquid for the
purposes of recreation drug use, consuming it regularly
(about 20 times) until one month ago (October 2011).
The patient’s last visit from the initial psychotic epi-
sode was in December 2011. In January of the following
year, the patient failed to attend his follow-up appoint-
ment and he was lost to follow-up. In June 2012, his
mother informed us that his psychosis had relapsed, al-
though he appeared to be normal in the intervening
months. The patient presented to us again in July 2012,
claiming that he was being harassed by people around
him and that this was related to suspicious activity with
his phone and computer. He also expressed that he was
again suspicious of his wife. He confided that he had
consumed another commercially available aromatic li-
quid twice in March. He was started on aripiprazole
6 mg/day, remaining in his delusional state through the
end of September 2012 despite continuing on the medi-
cation. Figure 1 shows the time course of the patient’s
drug ingestion and delusional state.
The brand names of the first aromatic liquids he con-
sumed was “GT 5me0 (Citrus Paradisi FLAVOR)”, though
their chemical ingredients were not clear. The patient had
purchased both 5-MeO-DIPT and these aromatic liquids






Figure 1 Time course of drug ingestion and delusional state. A. May 2
2011. Last visit from first episode. D. March 2012. Restarted consuming aromDiscussion
It is often difficult to gather information about a history
of drug abuse as patients often attempt to hide this from
evaluators. In this case, despite conducting careful inter-
views, it took several months to identify the patient’s
drug abuse. An evaluation of the chronological sequence
of the patient’s condition showed that these legal
aromatic liquids, which can be purchased easily on the
Internet, were very likely the trigger for the patient’s
delusional episodes, although according to users’ com-
ments available on the Internet, the use of these
aromatic liquids was not associated with delusion. We
suspect that these liquids may contain a psychoactive
substance, inducing his delusions. However, in each epi-
sode, the patient’s delusional state was prolonged on the
order of months; we found no prior reports of prolonged
delusions triggered by abusing legal substances.
We speculate that the patient’s past history of 5-MeO-
DIPT abuse played an important role. 5-MeO-DIPT is a
commonly abused hallucinogenic drug, illegal in many
countries, including Japan since 2005. There are many re-
ports of acute psychosis related to 5-MeO-DIPT use [4-7],
and its psychotomimetic effects have been considered to
be due to enhancement of serotonergic neurotransmission
and/or trace amine receptors [8]. The patient’s recurrent
abuse of 5-MeO-DIPT might have caused sensitization (or
reverse tolerance). Sensitization is the amplification of a
response following repeated administrations of a stimulus.
Relapse of amphetamine psychosis due to this mechanism
is well documented [9,10]. Similar relapses have been
reported with 5-MeO-DIPT, with one case report describ-
ing a patient experiencing a “bad trip” after hearing unex-
pected news [4]. It is possible that sensitization is the basis
of relapse, although this is not explicitly discussed. We
speculate that our patient’s response to ingesting the aro-
matic liquids was amplified, given that he had repeatedly







011. First visit. B. October 2011. Quit aromatic liquid. C. December
atic liquid. E. June 2012. First visit from second episode.
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5-MeO-DIPT was previously a popular drug of abuse,
and it is highly probable that many past 5-MeO-DIPT
users remain sensitized. This is an important latent
factor underlying subsequent episodes of drug-induced
psychoses. Psychiatrists should consider the possibility
of 5-MeO-DIPT sensitization when assessing patients
with acute psychoses.
We hypothesize that sensitization caused by 5-MeO-
DIPT exists not only in this case but also in many other
cases of acute psychotic episodes in drug abusers. Pro-
vided that more cases are added and sensitization caused
by 5-MeO-DIPT is clarified, further understanding may
be available in the field of psychosis related to substance
abuse.
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